Transatlantic, team-science grants to design, validate, and test interventions that prevent cancer recurrence or intercept early recurrent disease—combining U.S. and UK expertise, strong patient-advocate engagement, and a clear line of sight to clinical evaluation within two years.
Eligibility Criteria:
-
Collaborative team spanning the U.S. and UK with a Team Leader and Co-Leader (one based in the UK, the other in the U.S.), up to four additional Team Principals, a Project Manager, and at least two Patient Advocates.
-
Independent investigators (doctoral/medical degree) at academic/medical/research institutions; no for-profit or government employees as TL/TC/TP (they may participate as collaborators).
-
Focus on preclinical or later-stage translational research leading to patient studies within two years; proposals solely on discovery biology or detection without an intervention are out of scope.
Funding Details:
-
Awards from USD 1,000,000 to USD 4,000,000 total for 1–4 years (up to USD 8,000,000 available overall). Up to 10% indirect costs (none on UK activities). Senior-investigator salary support limited and not available for UK-based seniors; early-career and research staff support allowed. Milestone-based payments.
Deadline:
-
Letter of Intent due: October 1, 2025 (notification week of November 4, 2025).
-
Full Application due: January 21, 2026; virtual selection meeting: February 6, 2026; awards by March 2026; anticipated start by May 2026.
Where to Go for Further Information:
-
Submit via ProposalCentral; application templates and budget spreadsheets provided in the portal.
-
Program inquiries: [email protected].